title: Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study.
abstract: Adiponectin is a recently identified adipocyte-derived protein, which is associated with glucose metabolism, insulin sensitivity and adiposity. The aim of this study was to explore the alterations in serum adiponectin concentration during treatment with olanzapine or risperidone. Serum concentrations of adiponectin were investigated in body mass index (BMI, kg/m2)- and age-matched groups of non-diabetic, non-obese schizophrenic patients receiving a stable dose of olanzapine (n = 18) or risperidone (n = 15) for 4 weeks or more, and of mentally and physically healthy volunteers (n = 17). Patients undergoing treatment with olanzapine or risperidone had significantly higher adiponectin concentrations than the healthy volunteers, even after controlling for BMI. Adiponectin concentrations decreased with increasing BMI in patients taking olanzapine, while elevated levels were observed in patients taking risperidone, regardless of adiposity. This preliminary cross-sectional study indicates that adiponectin is involved in the regulation of glucose metabolism and weight in schizophrenic patients during treatment with olanzapine or risperidone, presumably showing a normalizing effect on metabolic abnormality.
authors.affiliation: Department of Psychiatry, Yokohama Maioka Hospital, Yokohama, Japan. togo-t@rd6.so-net.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Togo
authors.forename: Katsuo
authors.initials: K
authors.lastname: Kojima
authors.forename: Mika
authors.initials: M
authors.lastname: Shoji
authors.forename: Akihiko
authors.initials: A
authors.lastname: Kase
authors.forename: Hirotake
authors.initials: H
authors.lastname: Uchikado
authors.forename: Omi
authors.initials: O
authors.lastname: Katsuse
authors.forename: Eizo
authors.initials: E
authors.lastname: Iseki
authors.forename: Kenji
authors.initials: K
authors.lastname: Kosaka
mesh_terms: D052242:Adiponectin; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D000077152:Olanzapine; D010865:Pilot Projects; D011506:Proteins / Q000378:metabolism*; D018967:Risperidone / Q000009:adverse effects*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy; D044967:Serum
chemical_list: D052242:Adiponectin; D014150:Antipsychotic Agents; D001786:Blood Glucose; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine